These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24152331)

  • 1. Editorial: pharmacological intervention for Down syndrome cognitive deficits: emerging drug targets.
    Montesinos ML
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):6-7. PubMed ID: 24152331
    [No Abstract]   [Full Text] [Related]  

  • 2. Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome.
    Ruparelia A; Pearn ML; Mobley WC
    Curr Opin Neurobiol; 2012 Oct; 22(5):880-6. PubMed ID: 22658745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Perspectives for the Rescue of Cognitive Disability in Down Syndrome.
    Bartesaghi R; Haydar TF; Delabar JM; Dierssen M; Martínez-Cué C; Bianchi DW
    J Neurosci; 2015 Oct; 35(41):13843-52. PubMed ID: 26468184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Down syndrome be treated?
    Underwood E
    Science; 2014 Feb; 343(6174):964-7. PubMed ID: 24578561
    [No Abstract]   [Full Text] [Related]  

  • 5. Allelic variability in D21S11, but not in APP or APOE, is associated with cognitive decline in Down syndrome.
    Farrer MJ; Crayton L; Davies GE; Oliver C; Powell J; Holland AJ; Kessling AM
    Neuroreport; 1997 May; 8(7):1645-9. PubMed ID: 9189907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathways to cognitive deficits in Down syndrome.
    Sturgeon X; Le T; Ahmed MM; Gardiner KJ
    Prog Brain Res; 2012; 197():73-100. PubMed ID: 22541289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.
    Lee SE; Duran-Martinez M; Khantsis S; Bianchi DW; Guedj F
    Trends Mol Med; 2020 Feb; 26(2):150-169. PubMed ID: 31706840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down syndrome: genes, model systems, and progress towards pharmacotherapies and clinical trials for cognitive deficits.
    Busciglio J; Capone G; O'Bryan J; Gardiner KJ
    Cytogenet Genome Res; 2013; 141(4):260-71. PubMed ID: 24008277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down's syndrome protein identified.
    Rosania K
    Lab Anim (NY); 2013 May; 42(5):153. PubMed ID: 23604146
    [No Abstract]   [Full Text] [Related]  

  • 10. Down syndrome: the crucible for treating genomic imbalance.
    Korenberg JR
    Genet Med; 2009 Sep; 11(9):617-9. PubMed ID: 19690507
    [No Abstract]   [Full Text] [Related]  

  • 11. Gene-dosage effect on chromosome 21 transcriptome in trisomy 21: implication in Down syndrome cognitive disorders.
    Kahlem P
    Behav Genet; 2006 May; 36(3):416-28. PubMed ID: 16557362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing GABAergic inhibition restores cognitive functions in a mouse model of Down syndrome.
    Potier MC; Braudeau J; Dauphinot L; Delatour B
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):8-15. PubMed ID: 24152333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.
    Gardiner KJ
    Drug Des Devel Ther; 2015; 9():103-25. PubMed ID: 25552901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human and mouse model cognitive phenotypes in Down syndrome: implications for assessment.
    Edgin JO; Mason GM; Spanò G; Fernández A; Nadel L
    Prog Brain Res; 2012; 197():123-51. PubMed ID: 22541291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Akt-mTOR pathway in Down's syndrome: the potential use of rapamycin/rapalogs for treating cognitive deficits.
    Troca-Marín JA; Casañas JJ; Benito I; Montesinos ML
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):34-40. PubMed ID: 24152334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down syndrome: advances in molecular biology and the neurosciences.
    Capone GT
    J Dev Behav Pediatr; 2001 Feb; 22(1):40-59. PubMed ID: 11265922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
    de la Torre R; de Sola S; Hernandez G; Farré M; Pujol J; Rodriguez J; Espadaler JM; Langohr K; Cuenca-Royo A; Principe A; Xicota L; Janel N; Catuara-Solarz S; Sanchez-Benavides G; Bléhaut H; Dueñas-Espín I; Del Hoyo L; Benejam B; Blanco-Hinojo L; Videla S; Fitó M; Delabar JM; Dierssen M;
    Lancet Neurol; 2016 Jul; 15(8):801-810. PubMed ID: 27302362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relevance of animal models in the study of human pathologies: a mouse model of Down syndrome].
    Morice E
    Biol Aujourdhui; 2010; 204(1):3-8. PubMed ID: 20950569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials in children with Down syndrome: issues from a cognitive research perspective.
    Heller JH; Spiridigliozzi GA; Crissman BG; Sullivan-Saarela JA; Li JS; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2006 Aug; 142C(3):187-95. PubMed ID: 16838317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetics: the neglected key to minimize learning and memory deficits in Down syndrome.
    Dekker AD; De Deyn PP; Rots MG
    Neurosci Biobehav Rev; 2014 Sep; 45():72-84. PubMed ID: 24858130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.